Individuel survivorship program for ovarian cancer patients based on PROM and shared decision making - PROMova

Anette Stolberg Kargo, Angela Coulter, Niels Henrik Ingvar Hjøllund, Pernille Tine Jensen, Karina Dahl Steffensen

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review


Around 500 women are diagnosed with ovarian cancer each year and 70-80% will have advanced disease at the time of diagnosis. Despite excellent response to chemotherapy 80-85% of patients will experience a relapse. In 2015 the Danish Health Authorities initiated major changes in follow-up arrangements for these patients on the grounds that routine monitoring is ineffective and that follow-up should be individualized. These changes have caused concern among clinicians who fear that omission of routine examinations will hamper detection of recurrence, since clinical symptoms of relapse can be diffuse. Patient-Reported Outcome Measures (PROMs) are tools designed to improve the focus on patients’ needs and symptoms, but little is known about their use during cancer follow up, especially regarding patients’ preferences and needs. This study aims to assess the feasibility of using PROMs during follow-up as a means of incorporating patients’ knowledge, needs and preferences to create an individualized follow up program.

Materials and methods:
Women diagnosed with ovarian cancer who have completed first line treatment and entered follow up are being recruited to the study, including those receiving Bevacizumab treatment, and all oncology departments in Denmark have been invited to participate in PROMova. We aim to recruit 300 patients, all of whom will be followed-up for 3 years whether or not they experience a recurrence.

Recruitment is in progress with 13 patients recruited to date. Data collection is ongoing.

The use of PROMs could potentially enhance understanding of patients’ preferences and needs in their follow up programme and thereby improve the quality of life of women with ovarian cancer. The strategic and ongoing cooperation between DGCG, KIU and the Danish Cancer Society will aim to make recommendations on the use of PROMs in ovarian cancer follow up, including their potential for clinical implementation after the research period.
StatusUdgivet - 2017
BegivenhedDGCG Årsmøde 2017 - Ålborg, Danmark
Varighed: 3. mar. 20173. mar. 2017


SeminarDGCG Årsmøde 2017